-
1
-
-
73349094086
-
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
-
19843557
-
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The New England journal of medicine. 2009; 361(23):2209-20. doi: 10.1056/NEJMoa0908492 PMID: 19843557.
-
(2009)
The New England Journal of Medicine
, vol.361
, Issue.23
, pp. 2209-2220
-
-
Rerks-Ngarm, S.1
Pitisuttithum, P.2
Nitayaphan, S.3
Kaewkungwal, J.4
Chiu, J.5
Paris, R.6
-
2
-
-
33845433434
-
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
-
17109337
-
Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. The Journal of infectious diseases. 2006; 194 (12):1661-71. doi: 10.1086/508748 PMID: 17109337.
-
(2006)
The Journal of Infectious Diseases
, vol.194
, Issue.12
, pp. 1661-1671
-
-
Pitisuttithum, P.1
Gilbert, P.2
Gurwith, M.3
Heyward, W.4
Martin, M.5
Van Griensven, F.6
-
3
-
-
13944254982
-
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
-
15688278
-
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. The Journal of infectious diseases. 2005; 191(5):654-65. doi: 10.1086/428404 PMID: 15688278.
-
(2005)
The Journal of Infectious Diseases
, vol.191
, Issue.5
, pp. 654-665
-
-
Flynn, N.M.1
Forthal, D.N.2
Harro, C.D.3
Judson, F.N.4
Mayer, K.H.5
Para, M.F.6
-
4
-
-
84887865083
-
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine
-
24099601 Epub 2013/10/09. PubMed Central PMCID: PMC4030634
-
Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013; 369(22):2083-92. Epub 2013/10/09. doi: 10.1056/NEJMoa1310566 PMID: 24099601; PubMed Central PMCID: PMC4030634.
-
(2013)
N Engl J Med.
, vol.369
, Issue.22
, pp. 2083-2092
-
-
Hammer, S.M.1
Sobieszczyk, M.E.2
Janes, H.3
Karuna, S.T.4
Mulligan, M.J.5
Grove, D.6
-
5
-
-
56649105122
-
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial
-
19012954 PubMed Central PMCID: PMC2721012
-
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3 PMID: 19012954; PubMed Central PMCID: PMC2721012.
-
(2008)
Lancet
, vol.372
, Issue.9653
, pp. 1881-1893
-
-
Buchbinder, S.P.1
Mehrotra, D.V.2
Duerr, A.3
Fitzgerald, D.W.4
Mogg, R.5
Li, D.6
-
6
-
-
84899445004
-
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: Unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study
-
24560541 Epub 2014/02/25. PubMed Central PMCID: PMC4174314
-
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014; 14(5):388-96. Epub 2014/02/25. doi: 10.1016/S1473-3099(14)70020-9 PMID: 24560541; PubMed Central PMCID: PMC4174314.
-
(2014)
Lancet Infect Dis.
, vol.14
, Issue.5
, pp. 388-396
-
-
Gray, G.E.1
Moodie, Z.2
Metch, B.3
Gilbert, P.B.4
Bekker, L.G.5
Churchyard, G.6
-
7
-
-
84874433635
-
Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity
-
23151505 PubMed Central PMCID: PMC3528489
-
Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(50):E3503-12. doi: 10.1073/pnas.1208972109 PMID: 23151505; PubMed Central PMCID: PMC3528489.
-
(2012)
Proceedings of the National Academy of Sciences of the United States of America
, vol.109
, Issue.50
, pp. E3503-E3512
-
-
Zak, D.E.1
Andersen-Nissen, E.2
Peterson, E.R.3
Sato, A.4
Hamilton, M.K.5
Borgerding, J.6
-
8
-
-
78149417692
-
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: A randomized clinical trial (HVTN 054)
-
21048953 PubMed Central PMCID: PMC2965084
-
Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PloS one. 2010; 5(10):e13579. doi: 10.1371/journal.pone.0013579 PMID: 21048953; PubMed Central PMCID: PMC2965084.
-
(2010)
PLoS One
, vol.5
, Issue.10
, pp. e13579
-
-
Peiperl, L.1
Morgan, C.2
Moodie, Z.3
Li, H.4
Russell, N.5
Graham, B.S.6
-
9
-
-
77958498605
-
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa
-
20877623 PubMed Central PMCID: PMC2943475
-
Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PloS one. 2010; 5(9):e12873. doi: 10.1371/journal.pone.0012873 PMID: 20877623; PubMed Central PMCID: PMC2943475.
-
(2010)
PLoS One
, vol.5
, Issue.9
, pp. e12873
-
-
Jaoko, W.1
Karita, E.2
Kayitenkore, K.3
Omosa-Manyonyi, G.4
Allen, S.5
Than, S.6
-
10
-
-
79955774295
-
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults
-
20854108 PubMed Central PMCID: PMC3422055
-
Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, et al. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS research and human retroviruses. 2010. doi: 10.1089/AID.2010.0151 PMID: 20854108; PubMed Central PMCID: PMC3422055.
-
(2010)
AIDS Research and Human Retroviruses
-
-
Nicholson, O.1
Dicandilo, F.2
Kublin, J.3
Sun, X.4
Quirk, E.5
Miller, M.6
-
11
-
-
75749141272
-
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)
-
20078213 PubMed Central PMCID: PMC2811694
-
Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). The Journal of infectious diseases. 2010; 201(4):600-7. doi: 10.1086/650299 PMID: 20078213; PubMed Central PMCID: PMC2811694.
-
(2010)
The Journal of Infectious Diseases
, vol.201
, Issue.4
, pp. 600-607
-
-
Kibuuka, H.1
Kimutai, R.2
Maboko, L.3
Sawe, F.4
Schunk, M.S.5
Kroidl, A.6
-
12
-
-
79961048088
-
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)
-
21857901 PubMed Central PMCID: PMC3152265
-
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PloS one. 2011; 6(8):e21225. doi: 10.1371/journal.pone.0021225 PMID: 21857901; PubMed Central PMCID: PMC3152265.
-
(2011)
PLoS One
, vol.6
, Issue.8
, pp. e21225
-
-
Churchyard, G.J.1
Morgan, C.2
Adams, E.3
Hural, J.4
Graham, B.S.5
Moodie, Z.6
-
13
-
-
69749111528
-
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults
-
19605598 PubMed Central PMCID: PMC2745015
-
Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clinical and vaccine immunology: CVI. 2009; 16 (9):1285-92. doi: 10.1128/CVI.00144-09 PMID: 19605598; PubMed Central PMCID: PMC2745015.
-
(2009)
Clinical and Vaccine Immunology: CVI
, vol.16
, Issue.9
, pp. 1285-1292
-
-
Harro, C.1
Sun, X.2
Stek, J.E.3
Leavitt, R.Y.4
Mehrotra, D.V.5
Wang, F.6
-
14
-
-
66149156475
-
Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials
-
19339347 PubMed Central PMCID: PMC2687372
-
Koup RA, Lamoreaux L, Zarkowsky D, Bailer RT, King CR, Gall JG, et al. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. Journal of virology. 2009; 83(12):6318-22. doi: 10.1128/JVI.00384-09 PMID: 19339347; PubMed Central PMCID: PMC2687372.
-
(2009)
Journal of Virology
, vol.83
, Issue.12
, pp. 6318-6322
-
-
Koup, R.A.1
Lamoreaux, L.2
Zarkowsky, D.3
Bailer, R.T.4
King, C.R.5
Gall, J.G.6
-
15
-
-
60549106905
-
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults
-
19108693 PubMed Central PMCID: PMC3256563
-
Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS research and human retroviruses. 2009; 25(1):103-14. doi: 10.1089/aid.2008.0212 PMID: 19108693; PubMed Central PMCID: PMC3256563.
-
(2009)
AIDS Research and Human Retroviruses
, vol.25
, Issue.1
, pp. 103-114
-
-
Harro, C.D.1
Robertson, M.N.2
Lally, M.A.3
O'Neill, L.D.4
Edupuganti, S.5
Goepfert, P.A.6
-
16
-
-
84862904805
-
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)
-
22561365 Epub 2012/05/09. PubMed Central PMCID: PMC3490694
-
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012; 206(2):258-66. Epub 2012/05/09. doi: 10.1093/infdis/jis342 PMID: 22561365; PubMed Central PMCID: PMC3490694.
-
(2012)
J Infect Dis.
, vol.206
, Issue.2
, pp. 258-266
-
-
Duerr, A.1
Huang, Y.2
Buchbinder, S.3
Coombs, R.W.4
Sanchez, J.5
Del Rio, C.6
-
17
-
-
79959301474
-
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study
-
21570355 PubMed Central PMCID: PMC3417349
-
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. The Lancet Infectious diseases. 2011; 11 (7):507-15. doi: 10.1016/S1473-3099(11)70098-6 PMID: 21570355; PubMed Central PMCID: PMC3417349.
-
(2011)
The Lancet Infectious Diseases
, vol.11
, Issue.7
, pp. 507-515
-
-
Gray, G.E.1
Allen, M.2
Moodie, Z.3
Churchyard, G.4
Bekker, L.G.5
Nchabeleng, M.6
-
18
-
-
62749200441
-
Host immune responses to chronic adenovirus infections in human and nonhuman primates
-
19116257 PubMed Central PMCID: PMC2648267
-
Calcedo R, Vandenberghe LH, Roy S, Somanathan S, Wang L, Wilson JM. Host immune responses to chronic adenovirus infections in human and nonhuman primates. Journal of virology. 2009; 83 (6):2623-31. doi: 10.1128/JVI.02160-08 PMID: 19116257; PubMed Central PMCID: PMC2648267.
-
(2009)
Journal of Virology
, vol.83
, Issue.6
, pp. 2623-2631
-
-
Calcedo, R.1
Vandenberghe, L.H.2
Roy, S.3
Somanathan, S.4
Wang, L.5
Wilson, J.M.6
-
19
-
-
84860390074
-
Adenovirus type 5 induces Vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells
-
21289616 PubMed Central PMCID: PMC3097311
-
Ganguly S, Manicassamy S, Blackwell J, Pulendran B, Amara RR. Adenovirus type 5 induces vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells. Mucosal immunology. 2011; 4(5):528-38. doi: 10.1038/mi.2011.1 PMID: 21289616; PubMed Central PMCID: PMC3097311.
-
(2011)
Mucosal Immunology
, vol.4
, Issue.5
, pp. 528-538
-
-
Ganguly, S.1
Manicassamy, S.2
Blackwell, J.3
Pulendran, B.4
Amara, R.R.5
-
20
-
-
73949119632
-
Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1
-
19918060 PubMed Central PMCID: PMC2785271
-
Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, Hayes P, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(47):19940-5. doi: 10.1073/pnas.0907898106 PMID: 19918060; PubMed Central PMCID: PMC2785271.
-
(2009)
Proceedings of the National Academy of Sciences of the United States of America
, vol.106
, Issue.47
, pp. 19940-19945
-
-
Benlahrech, A.1
Harris, J.2
Meiser, A.3
Papagatsias, T.4
Hornig, J.5
Hayes, P.6
-
21
-
-
84914695671
-
Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development
-
25349379 PubMed Central PMCID: PMC4226080
-
Lewis GK, DeVico AL, Gallo RC. Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(44):15614-21. doi: 10.1073/pnas.1413550111 PMID: 25349379; PubMed Central PMCID: PMC4226080.
-
(2014)
Proceedings of the National Academy of Sciences of the United States of America
, vol.111
, Issue.44
, pp. 15614-15621
-
-
Lewis, G.K.1
DeVico, A.L.2
Gallo, R.C.3
-
22
-
-
77955430749
-
Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa
-
20588163 PubMed Central PMCID: PMC2914808
-
Cohen CR, Moscicki AB, Scott ME, Ma Y, Shiboski S, Bukusi E, et al. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. Aids. 2010; 24(13):2069-74. doi: 10.1097/QAD.0b013e32833c323b PMID: 20588163; PubMed Central PMCID: PMC2914808.
-
(2010)
AIDS
, vol.24
, Issue.13
, pp. 2069-2074
-
-
Cohen, C.R.1
Moscicki, A.B.2
Scott, M.E.3
Ma, Y.4
Shiboski, S.5
Bukusi, E.6
-
23
-
-
84907494055
-
The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier
-
25268493 PubMed Central PMCID: PMC4182607
-
Lemos MP, Lama JR, Karuna ST, Fong Y, Montano SM, Ganoza C, et al. The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier. PloS one. 2014; 9(9):e108954. doi: 10.1371/journal.pone.0108954 PMID: 25268493; PubMed Central PMCID: PMC4182607.
-
(2014)
PLoS One
, vol.9
, Issue.9
, pp. e108954
-
-
Lemos, M.P.1
Lama, J.R.2
Karuna, S.T.3
Fong, Y.4
Montano, S.M.5
Ganoza, C.6
|